Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2017

View Archived Issues

Hope Biosciences acquires rights to nuc-gemcitabine from AptaBio

JNK1 as a novel therapeutic target for anxiety and depressive-like disorders

AbbVie begins phase II trials of anti-tau antibody

Aldeyra Therapeutics gives update on phase III program for ADX-102

Relmada Therapeutics cleared to conduct phase IIa study of d-methadone for depression

First-in-human data for 10-1074 in HIV-1-infected individuals

Phase II data shows superior efficacy of pritelivir over valacyclovir against genital HSV-2

Johnson & Johnson to acquire Actelion

DelMar and MD Anderson begin phase II study of VAL-083 in glioblastoma

Merck KGaA reports findings from phase Ib study of M-1095 in psoriasis

Gilead describes new Tpl-2/Cot inhibitors

Zhejiang Hisun Pharmaceutical patents glucagon receptor antagonists

Ossianix receives milestone payment from Lundbeck

Neovia initiates phase I trial of NEV-801 in advanced cancers

Cue Biopharma announces invested capital to develop next-generation biologics

Lundbeck discovers novel PDE9 inhibitors

Bayer Pharma presents new bromodomain-containing protein 4 inhibitors

Galleon Pharmaceuticals divulges new breathing control modulating compounds

Sumitomo Dainippon Pharma completes acquisition of Tolero Pharmaceuticals

Verapamil studied in patients with chronic rhinosinusitis with nasal polyps

Heidelberg Pharma signs license agreement with Max Delbruck Center

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ASH 2025: New blood cancer therapies trump chemo, older drugs
BioWorld
Targeted therapies and immunotherapies continue to show better results than chemotherapy in investigator-initiated and company-sponsored cancer trials, and newer...